Loading...
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.
Korpanty, Grzegorz Smyth, Elizabeth Sullivan, Laura A Brekken, Rolf A Carney, Desmond N
Korpanty, Grzegorz
Smyth, Elizabeth
Sullivan, Laura A
Brekken, Rolf A
Carney, Desmond N
Advisors
Editors
Other Contributors
Date
2010-01
Date Submitted
Keywords
Other Subjects
Subject Mesh
Angiogenesis Inhibitors
Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung
Clinical Trials as Topic
Humans
Lung Neoplasms
Neovascularization, Pathologic
Piperidines
Quinazolines
Receptor, Epidermal Growth Factor
Receptors, Vascular Endothelial Growth Factor
Vascular Endothelial Growth Factor A
Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung
Clinical Trials as Topic
Humans
Lung Neoplasms
Neovascularization, Pathologic
Piperidines
Quinazolines
Receptor, Epidermal Growth Factor
Receptors, Vascular Endothelial Growth Factor
Vascular Endothelial Growth Factor A
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Alternative Titles
Publisher
Abstract
Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.
Language
en
ISSN
1535-3699
eISSN
ISBN
DOI
10.1258/ebm.2009.009191
PMID
20404013